Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication

Idorsia has suffered another setback in the clinic. A phase 2a trial of the selective orexin-1 antagonist ACT-539313 in binge eating disorder missed the mark, prompting the Actelion spinout to give up on the indication.